a unique identifier given to every patient included. The first letter represents the center where the patient got included (H: Georges Pompidou European Hospital, L: Lariboisière Hospital, MG: Namur Universitary Hospital, R: Rothschild Hospital, T: Charles Foix Hospital - "Triade" department, U: Charles Foix Hospital - "UGA" department)
date of birth
age of the patient at the time of inclusion
doac treatment (A: apixaban, D: dabigatran, R: rivaroxaban)
1 if the patient was included in the ADAGE sub-cohort studied for the article published in Thrombosis and Haemostasis in 2023, else 0
doac dose regimen, in mg
number of samples gathered
value of measured DOAC Cmax, in ng/mL
value of measured DOAC Cmin, in ng/mL
D-dimer level at Cmax, in µg/mL
D-dimer level at Cmin, in µg/mL
fibrinogen level at inclusion
hospital where the patient was included
date of inclusion
sex of the patient (1 for females, 0 for males)
weight, in kg
height, in cm
blood pressure, in mmHg
heart failure (1 if yes, 0 if no)
liver failure (1 if yes, 0 if no)
alcoholism (1 if yes, 0 if no)
coronary heart disease (1 if yes, 0 if no)
stroke history (1 if yes, 0 if no)
solid cancer history (1 if yes, 0 if no)
haemopathy history (1 if yes, 0 if no)
demencia history (1 if yes, 0 if no)
CIRS-G (Cumulative Illness Rating Scale) score
modified CIRS-G score
type of atrial fibrillation (paroxysmal = 1 ; persistent = 2 ; permanent = 3)
high blood pressure (1 if yes, 0 if no)',
diabetes history (1 if yes, 0 if no)
dyslipidaemia (1 if yes, 0 if no)
active smoking (1 if yes, 0 if no)
obesity (1 if yes, 0 if no)
CHA2DS2–VASc score
HAS-BLED score
Hemorr2hages score
number of unique medications taken daily in addition to the DOAC
list of unique medications taken
treated with amiodarone (1 if yes, 0 if no)
treated with verapamil (1 if yes, 0 if no)
treated with quinidine (1 if yes, 0 if no)
treated with clarithromycin (1 if yes, 0 if no)
treated with aspirin (1 if yes, 0 if no)
treated with clopidogrel (1 if yes, 0 if no)
treated with another anti-platelet medication (1 if yes, 0 if no)
treated with nsaid (1 if yes, 0 if no)
treated with beta-blocker (1 if yes, 0 if no)
treated with acei (1 if yes, 0 if no)
treated with arbs (1 if yes, 0 if no)
treated with statin (1 if yes, 0 if no)
creatinine in µmol/L
creatinine clearance estimed by Cockcroft & Gault formula, in mL/min
creatinine clearance estimed by MDRD formula, in mL/min
creatinine clearance estimed by CKD-EPI formula, in mL/min
C-reactive protein, in mg/mL
albumin, in g/L
haemoglobin, in g/dL
platelets, in G/L
leucocytes, in G/L
aspartate transaminase, expressed as a number of times the normal
alanine transaminase, expressed as a number of times the normal
gamma-glutamyltransferase, expressed as a number of times the normal
alkaline phosphatase, expressed as a number of times the normal
bilirubin, expressed as a number of times the normal
date of DOAC treatment initiation
patient has completed the 6-month follow-up (1 if yes, 0 if no)
patient was hospitalised in the 6-month period following inclusion (1 if yes, 0 if no)
patient received a blood transfusion in the 6-month period following inclusion (1 if yes, 0 if no)
patient reported a bleeding event in the 6-month period following inclusion (1 if yes, 0 if no)
type of bleeding reported at the 6-month follow-up
date of bleeding event reported at the 6-month follow-up
patient reported a thrombo-embolic event in the 6-month period following inclusion (1 if yes, 0 if no)
type of thrombo-embolic event reported at the 6-month follow-up
date of thrombo-embolic event reported at the 6-month follow-up
patient died within 6 months of inclusion
date of death, if patient died within 6 month of inclusion
six months from inclusion, the patient is still treated by DOAC (1 if yes, 0 if no)
patient has completed the 12-month follow-up (1 if yes, 0 if no)
patient was hospitalised in the 12-month period following inclusion (1 if yes, 0 if no)
patient received a blood transfusion in the 12-month period following inclusion (1 if yes, 0 if no)
patient reported a bleeding event in the 12-month period following inclusion (1 if yes, 0 if no)
type of bleeding reported at the 12-month follow-up
date of bleeding event reported at the 12-month follow-up
patient reported a thrombo-embolic event in the 12-month period following inclusion (1 if yes, 0 if no)
type of thrombo-embolic event reported at the 12-month follow-up
date of thrombo-embolic event reported at the 12-month follow-up
patient died within 12 month of inclusion
date of death, if patient died within 12 month of inclusion
twelve months from inclusion, the patient is still treated by DOAC (1 if yes, 0 if no)
body mass index, in kg/m²
patient C-reactive protein level is above 5 mg/mL (1 if yes, 0 if no)
kidney failure according to Cockcroft & Gault formula (0: creatinine clearance > 90 mL/min, 1: creatinine clearance between 61 and 90 mL/min, 2: creatinine clearance between 31 and 60 mL/min, 3: creatinine clearance ≤ 30 mL/min)
kidney failure according to Cockcroft & Gault formula (1: creatinine clearance < 50 mL/min, 0: creatinine clearance ≥ 50 mL/min)
number of medications that are substrates of P-glycoprotein
number of medications that are inhibitors of P-glycoprotein
number of medications that are substrates or inhibitors of P-glycoprotein
patient takes at least 1 medication that is substrate or inhibitor of P-glycoprotein (1 if yes, 0 if no)
patient takes at least 1 medication that is a substrate of P-glycoprotein (1 if yes, 0 if no)
patient takes at least 1 medication that is an inhibitor of P-glycoprotein (1 if yes, 0 if no)
number of medications that are substrates of CYP3A4
number of medications that are inhibitors of CYP3A4
number of medications that are inductors of CYP3A4
number of medications that are substrates, inhibitors or inductors of CYP3A4
patient takes at least 1 medication that is substrate, inhibitor or inductor of CYP3A4 (1 if yes, 0 if no)
patient takes at least 1 medication that is substrate of CYP3A4 (1 if yes, 0 if no)
patient takes at least 1 medication that is an inhibitor of CYP3A4 (1 if yes, 0 if no)
treated with ssri (1 if yes, 0 if no)
treated with snra (1 if yes, 0 if no)
treated with ssri or snra (1 if yes, 0 if no)
treated with another anticoagulant, in addition to DOAC (1 if yes, 0 if no)
treated with amlodipine (1 if yes, 0 if no)
treated with alprazolam (1 if yes, 0 if no)
treated with atorvastatin (1 if yes, 0 if no)
treated with bisoprolol (1 if yes, 0 if no)
treated with citalopram (1 if yes, 0 if no)
treated with diazepam (1 if yes, 0 if no)
treated with diltiazem (1 if yes, 0 if no)
treated with digoxin (1 if yes, 0 if no)
treated with irbesartan (1 if yes, 0 if no)
treated with lansoprazole (1 if yes, 0 if no)
treated with losartan (1 if yes, 0 if no)
treated with mirtazapine (1 if yes, 0 if no)
treated with oxycodone (1 if yes, 0 if no)
treated with tamsulosin (1 if yes, 0 if no)
treated with simvastatin (1 if yes, 0 if no)
treated with zopiclone or zolpidem (1 if yes, 0 if no)
history of solid cancer or haemopathy (1 if yes, 0 if no)
platelets in normal range (1 if yes, 0 if no)
hyperleucocytosis (1 if yes, 0 if no)
treated with triazole antifungal (1 if yes, 0 if no)
treated with antiarrythmics (1 if yes, 0 if no)
treated with any anti-platelets medication (1 if yes, 0 if no)
doac treatement duration at inclusion (in month)
patient lost to follow-up before 6 months
patient lost to follow-up before 12 months
patient reported a bleeding event in either the 6-month or 12-month period following inclusion (1 if yes, 0 if no)
patient reported a thrombo-embolic event in either the 6-month or 12-month period following inclusion (1 if yes, 0 if no)
patient reported a bleeding event that was classified as major, according to ISTH criteria, in either the 6-month or 12-month period following inclusion (1 if yes, 0 if no)
patient reported a bleeding event that was classified as major, according to ISTH criteria, in the 6-month period following inclusion (1 if yes, 0 if no)
patient reported a bleeding event that was classified as major, according to ISTH criteria, in the 12-month period following inclusion (1 if yes, 0 if no)
id of the bleeding event reported at 6-month follow up (characterized in a dedicated database)
id of the thrombo-embolic event reported at 6-month follow up (characterized in a dedicated database)
time after inclusion at which the thrombo-embolic event occurred
time after inclusion at which the bleeding event occurred, in months
time after inclusion at which death occurred, in months
patient has been phenotyped (1 if yes, 0 if no)
genotype for ABCB1 exon 21 (GG = wild type, T or A = muted allele)
genotype for ABCB1 exon 26 (CC = wild type, T = muted allele)
genotype for ABCB1 exon 12 (CC = wild type, T = muted allele)
genotype for CYP2J2 (GG = wild type, T = muted allele)
genotype for CYP3A5 (AA = wild type, G = muted allele)
at least one of patient's sample was analysed by thrombin generation (any method)
at least one of patient's sample was analysed by fibrinogrpahy (Thrombodynamics)
at least one of patient's sample was analysed by thrombinography (Thrombodynamics)
at least one of patient's sample was analysed by DrugScreen (St-Genesia)
at least one of patient's sample was analysed by ThromboScreen without thrombomodulin (St-Genesia)
at least one of patient's sample was analysed by ThromboScreen with thrombomodulin (St-Genesia)
patient DOAC regimen is not in compliance with European Society of Cardiology's recommendations
DOAC regimen in compliance with European Society of Cardiology's recommendations
DOAC dose below European Society of Cardiology recommendations
DOAC dose above European Society of Cardiology recommendations
rate of clot growth at Cmax, in µm/min
lag time (fibrinography) at Cmax, in min
initial rate of clot growth at Cmax, in µm/min
stationary rate of clot growth at Cmax, in µm/min
clot size (measured at 30 min) at Cmax, in µm
clot density at Cmax, in arbitrary units
time of spontaneous clotting at Cmax, in min
lag time or "LT" (thombodynamics) at Cmax, in min
peak height or "PH" (thombodynamics) at Cmax, in thrombin arbitrary units/L
time to peak or "TTP" (thombodynamics) at Cmax, in min
endogenous thrombin potential or "ETP" (thombodynamics) at Cmax, in thrombin arbitrary units * min/L
stationary amplitude of thrombin peak (thombodynamics) at Cmax, in thrombin arbitrary units/L
rate of thrombin peak propagation (thombodynamics) at Cmax, in µm/min
lag time or "LT" using DrugScreen (St-Genesia) at Cmax, in min
peak height or "PH" using DrugScreen (St-Genesia) at Cmax, in nM/L
time to peak or "TTP" using DrugScreen (St-Genesia) at Cmax, in min
endogenous thrombin potential or "ETP" using DrugScreen (St-Genesia) at Cmax, in nM*min/L
velocity index using DrugScreen (St-Genesia) at Cmax, in nM/min
start tail using DrugScreen (St-Genesia) at Cmax, in min
normalised lag time using DrugScreen (St-Genesia) at Cmax, expressed as a ratio
normalised peak height using DrugScreen (St-Genesia) at Cmax, expressed as a %
normalised time to peak using DrugScreen (St-Genesia) at Cmax, expressed as a ratio
normalised endogenous thrombin potential using DrugScreen (St-Genesia) at Cmax, expressed as a %
normalised velocity index using DrugScreen (St-Genesia) at Cmax, expressed as a %
normalised start tail using DrugScreen (St-Genesia) at Cmax, expressed as a ratio
lag time or "LT" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmax, in min
peak height or "PH" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmax, in nM/L
time to peak or "TTP" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmax, in min
endogenous thrombin potential or "ETP" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmax, in nM*min/L
velocity index using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmax, in nM/min
start tail using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmax, in min
lag time or "LT" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, in min
peak height or "PH" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, in nM/L
time to peak or "TTP" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, in min
endogenous thrombin potential or "ETP" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, in nM*min/L
velocity index using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, in nM/min
start tail using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, in min
normalised lag time using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, expressed as a ratio
normalised peak height using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, expressed as a %
normalised time to peak using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, expressed as a ratio
normalised endogenous thrombin potential using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, expressed as a %
normalised velocity index using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, in nM/min
normalised start tail using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmax, expressed as a ratio
percentage of inhibition of lag time by thrombomodulin (St-Genesia) at Cmax, expressed as a %
percentage of inhibition of peak height by thrombomodulin (St-Genesia) at Cmax, expressed as a %
percentage of inhibition of time to peak by thrombomodulin (St-Genesia) at Cmax, expressed as a %
percentage of inhibition of endogenous thrombin potential by thrombomodulin (St-Genesia) at Cmax, expressed as a %
percentage of inhibition of velocity index by thrombomodulin (St-Genesia) at Cmax, expressed as a %
percentage of inhibition of start tail by thrombomodulin (St-Genesia) at Cmax, expressed as a %
rate of clot growth at Cmin, in µm/min
lag time (fibrinography) at Cmin, in min
initial rate of clot growth at Cmin, in µm/min
stationary rate of clot growth at Cmin, in µm/min
clot size (measured at 30 min) at Cmin, in µm
clot density at Cmin, in arbitrary units
time of spontaneous clotting at Cmin, in min
lag time or "LT" (thombodynamics) at Cmin, in min
peak height or "PH" (thombodynamics) at Cmin, in thrombin arbitrary units/L
time to peak or "TTP" (thombodynamics) at Cmin, in min
endogenous thrombin potential or "ETP" (thombodynamics) at Cmin, in thrombin arbitrary units * min/L
stationary amplitude of thrombin peak (thombodynamics) at Cmin, in thrombin arbitrary units/L
rate of thrombin peak propagation (thombodynamics) at Cmin, in µm/min
lag time or "LT" using DrugScreen (St-Genesia) at Cmin, in min
peak height or "PH" using DrugScreen (St-Genesia) at Cmin, in nM/L
time to peak or "TTP" using DrugScreen (St-Genesia) at Cmin, in min
endogenous thrombin potential or "ETP" using DrugScreen (St-Genesia) at Cmin, in nM*min/L
velocity index using DrugScreen (St-Genesia) at Cmin, in nM/min
start tail using DrugScreen (St-Genesia) at Cmin, in min
normalised lag time using DrugScreen (St-Genesia) at Cmin, expressed as a ratio
normalised peak height using DrugScreen (St-Genesia) at Cmin, expressed as a %
normalised time to peak using DrugScreen (St-Genesia) at Cmin, expressed as a ratio
normalised endogenous thrombin potential using DrugScreen (St-Genesia) at Cmin, expressed as a %
normalised velocity index using DrugScreen (St-Genesia) at Cmin, expressed as a %
normalised start tail using DrugScreen (St-Genesia) at Cmin, expressed as a ratio
lag time or "LT" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmin, in min
peak height or "PH" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmin, in nM/L
time to peak or "TTP" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmin, in min
endogenous thrombin potential or "ETP" using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmin, in nM*min/L
velocity index using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmin, in nM/min
start tail using ThromboScreen in the presence of thrombomodulin (St-Genesia) at Cmin, in min
lag time or "LT" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, in min
peak height or "PH" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, in nM/L
time to peak or "TTP" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, in min
endogenous thrombin potential or "ETP" using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, in nM*min/L
velocity index using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, in nM/min
start tail using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, in min
normalised lag time using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, expressed as a ratio
normalised peak height using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, expressed as a %
normalised time to peak using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, expressed as a ratio
normalised endogenous thrombin potential using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, expressed as a %
normalised velocity index using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, in nM/min
normalised start tail using ThromboScreen in the absence of thrombomodulin (St-Genesia) at Cmin, expressed as a ratio
percentage of inhibition of lag time by thrombomodulin (St-Genesia) at Cmin, expressed as a %
percentage of inhibition of peak height by thrombomodulin (St-Genesia) at Cmin, expressed as a %
percentage of inhibition of time to peak by thrombomodulin (St-Genesia) at Cmin, expressed as a %
percentage of inhibition of endogenous thrombin potential by thrombomodulin (St-Genesia) at Cmin, expressed as a %
percentage of inhibition of velocity index by thrombomodulin (St-Genesia) at Cmin, expressed as a %
percentage of inhibition of start tail by thrombomodulin (St-Genesia) at Cmin, expressed as a %
encoded genotype for abcb1 exon 21 (0 = wild type, 1 = heterozygous, 2 = muted homozygous)
encoded genotype for abcb1 exon 26 (0 = wild type, 1 = heterozygous, 2 = muted homozygous)
encoded genotype for abcb1 exon 12 (0 = wild type, 1 = heterozygous, 2 = muted homozygous)
encoded genotype for CYP2J2 (0 = wild type, 1 = heterozygous, 2 = muted homozygous)
encoded genotype for CYP3A5 (0 = wild type, 1 = heterozygous, 2 = muted homozygous)